Angiotensin Receptor Regulation By Upstream Short Open Reading Frames
上游短开放阅读框对血管紧张素受体的调节
基本信息
- 批准号:8894076
- 负责人:
- 金额:$ 72.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-17 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAdverse eventAmino AcidsAngiotensin IIAngiotensin ReceptorAngiotensin Type 1a ReceptorAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsArgipressinArrestinsBiologyBlood PressureCardiovascular DiseasesCatecholaminesCause of DeathCellsChronicClinicalConfocal MicroscopyCough HeadachesDOCADietary SodiumDiseaseDizzinessElectrolyte BalanceElectrolytesEmbryoExonsFluid BalanceG-Protein-Coupled ReceptorsG-substrateGTP-Binding ProteinsGoalsGrowth Factor OncogenesHealthHomeostasisHumanHypertensionHypotensionHypovolemiaInjection of therapeutic agentIntakeInterventionIsotonic ExerciseKidneyLeadLiquid substanceMediatingMessenger RNAModelingMolecularOpen Reading FramesOxytocinPathway interactionsPatientsPeptidesPeripheralPharmaceutical PreparationsPhosphotransferasesPlayProtein KinaseProtein Kinase CProteinsPublic HealthRattusReceptor, Angiotensin, Type 1RegulationRenovascular HypertensionRisk FactorsRoleScientistSexual DysfunctionSignal PathwaySignal TransductionSignaling ProteinSodiumSodium ChlorideTestingTherapeuticUnited StatesVasopressinsWater consumptionWorkblood pressure reductionblood pressure regulationcitrate carriercompliance behaviordosageextracellularin vivoinhibitor/antagonistinsightkidney cellnovelnovel therapeuticspressurereceptorreceptor couplingsalt sensitive hypertensiontooltrafficking
项目摘要
DESCRIPTION (provided by applicant): Angiotensin II (Ang II) plays a key role in fluid homeostasis and blood pressure (BP). We have recently found that a seven amino acid peptide (PEP7) encoded within a short open reading frame in exon 2 of the 5' leader sequence of the angiotensin type 1a receptor (AT1aR) mRNA inhibits Ang II activation of extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) and regulates AT1aR trafficking in cells. PEP7 also markedly reduced Ang II-mediated sodium intake without having any effect on Ang II-mediated water intake and it antagonized Ang II- induced increases in BP. Aim 1 will determine the signaling mechanism by which PEP7 inhibits Erk1/2 activation. We will test the hypothesis that PEP7 inhibition of Erk1/2 activation is Ang II dependent and mediated via the AT1aR-G protein-independent ß-arrestin signaling pathway. We will also investigate PEP7 regulation of AT1aR vesicular trafficking by inhibiting AT1aR coupling to the ß-arrestin pathway using both pharmacological and molecular approaches, and confocal microscopy. Aim 2 will elucidate the mechanism by which PEP7 regulates fluid and electrolyte homeostasis. We will investigate PEP7 effects in vivo in pathophysiological models of elevated sodium intake including hyponatremic hypovolemia and isotonic hypovolemia as well as conditions that modulate central oxytocin and vasopressin pathways and those that selectively inhibit G protein-mediated protein kinase C and G protein-independent Erk1/2 signaling cascades. Aim 3 will determine if the antihypertensive effects of PEP7 are Ang II-dependent by investigating PEP7 effects on arterial pressure in models of Ang II- and catecholamine- dependent hypertension. We will also determine if PEP7 is effective at lowering BP in two models of salt-sensitivity and what role reduced sodium intake plays in these effects. By achieving these aims, we will gain insight into PEP7 biology that could be leveraged toward developing novel interventions for diseases that are worsened by dietary sodium, like salt- sensitive hypertension.
描述(由申请人提供):血管紧张素 II (Ang II) 在体液稳态和血压 (BP) 中发挥关键作用。我们最近发现,血管紧张素 1a 型受体 (AT1aR) mRNA 5' 前导序列的外显子 2 的短开放阅读框内编码的七氨基酸肽 (PEP7) 可抑制细胞外信号调节蛋白激酶 1 和 2 (Erk1/2) 的 Ang II 激活,并调节细胞内 AT1aR 的运输。 PEP7 还显着减少了 Ang II 介导的钠摄入量,而对 Ang II 介导的水摄入量没有任何影响,并且它拮抗 Ang II 诱导的血压升高。目标 1 将确定 PEP7 抑制 Erk1/2 激活的信号传导机制。我们将测试以下假设:PEP7 对 Erk1/2 激活的抑制是 Ang II 依赖性的,并通过 AT1aR-G 蛋白独立的 ß-arrestin 信号通路介导。我们还将使用药理学和分子方法以及共聚焦显微镜,通过抑制 AT1aR 与 ß-arrestin 通路的偶联来研究 PEP7 对 AT1aR 囊泡运输的调节。目标 2 将阐明 PEP7 调节体液和电解质稳态的机制。我们将研究 PEP7 在钠摄入量增加的病理生理模型中的体内作用,包括低钠性低血容量和等渗性低血容量,以及调节中枢催产素和加压素途径的条件以及选择性抑制 G 蛋白介导的蛋白激酶 C 和 G 蛋白独立的 Erk1/2 信号级联的条件。目标 3 将通过研究 PEP7 对 Ang II 和儿茶酚胺依赖性高血压模型中动脉压的影响来确定 PEP7 的抗高血压作用是否依赖于 Ang II。我们还将确定 PEP7 在两种盐敏感性模型中是否能有效降低血压,以及减少钠摄入量在这些作用中发挥什么作用。通过实现这些目标,我们将深入了解 PEP7 生物学,可用于开发针对因膳食钠而恶化的疾病(如盐敏感性高血压)的新型干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Willis K. Samson其他文献
Cardiovascular Hormones
心血管激素
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Willis K. Samson;Meghan M. Taylor - 通讯作者:
Meghan M. Taylor
Atrial natriuretic factor and the central nervous system.
心房钠尿因子和中枢神经系统。
- DOI:
10.1016/s0889-8529(18)30498-5 - 发表时间:
1987 - 期刊:
- 影响因子:4.5
- 作者:
Willis K. Samson - 通讯作者:
Willis K. Samson
The effect of fever on central α-MSH concentrations in the rabbit
发热对家兔中枢α-MSH浓度的影响
- DOI:
- 发表时间:
1981 - 期刊:
- 影响因子:3
- 作者:
Willis K. Samson;J. M. Lipton;J. Zimmer;J. Glyn - 通讯作者:
J. Glyn
Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro.
内皮素的垂体作用位点:体外选择性抑制催乳素释放。
- DOI:
- 发表时间:
1990 - 期刊:
- 影响因子:0
- 作者:
Willis K. Samson;K. Skala;B. Alexander;F. Huang - 通讯作者:
F. Huang
Willis K. Samson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Willis K. Samson', 18)}}的其他基金
Angiotensin Receptor Regulation By Upstream Short Open Reading Frames
上游短开放阅读框对血管紧张素受体的调节
- 批准号:
9005356 - 财政年份:2014
- 资助金额:
$ 72.69万 - 项目类别:
Angiotensin receptor regulation by upstream short open reading frames
上游短开放阅读框对血管紧张素受体的调节
- 批准号:
8773952 - 财政年份:2014
- 资助金额:
$ 72.69万 - 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
- 批准号:
6654925 - 财政年份:2002
- 资助金额:
$ 72.69万 - 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
- 批准号:
6798202 - 财政年份:2002
- 资助金额:
$ 72.69万 - 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
- 批准号:
6938576 - 财政年份:2002
- 资助金额:
$ 72.69万 - 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
- 批准号:
6544728 - 财政年份:2002
- 资助金额:
$ 72.69万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 72.69万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 72.69万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 72.69万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 72.69万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 72.69万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 72.69万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 72.69万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 72.69万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 72.69万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 72.69万 - 项目类别:














{{item.name}}会员




